A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789)
Latest Information Update: 04 Oct 2024
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Cisplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms KEYNOTE-789
- Sponsors Merck Sharp & Dohme Corp.
Most Recent Events
- 29 Aug 2024 This study has been Completed in France, According to European Clinical Trials Database record.
- 10 Oct 2023 Status changed from active, no longer recruiting to completed.
- 08 Aug 2023 Planned End Date changed from 15 Jun 2023 to 2 Oct 2023.